ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2566

Novel Therapeutic Compound Tuftsin-Phosphorylcholine Attenuate Collagen Induced Arthritis

Tomer Bashi1, Miri Blank1, Jasna Omersel2, Alexander Volkov3, Iris Barshack3 and Yehuda Shoenfeld1, 1Sheba Medical Center, Zabludowicz Center for Autoimmune Diseases, affiliated to affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel, 2Faculty of pharmacy, University of Ljublijana, Ljublijana, Slovenia, 3Sheba Medical Center, Institute of Pathology, affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Ramat Gan, Israel

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Animal models, animal models and therapy, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Animal Models Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Treatment with helminthes and ova from helminthes, improved clinical findings of several autoimmune diseases in patients and in animal models. We aimed to decipher the tolerogenic potential of Tuftsin- Phosphorylcholine (TPC), a helminth based compound in collagen induced arthritis (CIA) a mouse model of rheumatoid arthritis (RA).

Methods:

CIA DBA mice were treated with TPC, subcutaneously (5 µg/0.1 ml) or orally (250 µg/0.1 ml), starting 3 days before disease induction. The control groups were treated with PBS. Collagen antibodies were tested by ELISA, cytokines protein levels by DuoSet ELISA and T and B-regulatory cells phenotypes by FACS.

Results:

TPC treated mice had a significantly lower arthritis score 1.5 with comparison to the control mice 11.8 (p<0.0001) in both the subcutaneous and orally treated groups at Day 31. Moreover, histology analysis demonstrated highly inflamed joints in the CIA DBA mice, whereas the TPC treated mice maintained normal joint structure.  Moreover, TPC decreased the titers of circulating collagen II antibodies in the sera of the mice (p<0.0001) as well as enhanced the expression of IL-10 (p < 0.001), and inhibited the production of TNFα, IL-17 and IL-1β (p < 0.0001). TPC significantly expanded the CD4‏+CD25+‏FOXP3+‏ T-regulatory (Treg) cells and CD19+IL-10high+CD5highCD1dhighTIM-1+ B-regulatory (Breg) cells phenotypes (p < 0.0001) in the treated mice.

Conclusion:

Our data indicate that treatment with TPC attenuate CIA development in DBA mice which was exemplified by a low arthritic score, normal joints histology, reduced pro-inflammatory cytokines and increased anti-inflammatory cytokine expression, as well as expansion of Treg and Breg cells. Our results may lead to a new approach for a natural therapy for early RA patients.


Disclosure: T. Bashi, None; M. Blank, None; J. Omersel, None; A. Volkov, None; I. Barshack, None; Y. Shoenfeld, None.

To cite this abstract in AMA style:

Bashi T, Blank M, Omersel J, Volkov A, Barshack I, Shoenfeld Y. Novel Therapeutic Compound Tuftsin-Phosphorylcholine Attenuate Collagen Induced Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/novel-therapeutic-compound-tuftsin-phosphorylcholine-attenuate-collagen-induced-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/novel-therapeutic-compound-tuftsin-phosphorylcholine-attenuate-collagen-induced-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology